Compare Abbott Laboratories (ABT) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs PepsiCo, Inc. — how do they compare? Abbott Laboratories trades at $95.59 (market cap $166.94B), while PepsiCo, Inc. trades at $143.91 (market cap $198.15B). The key difference: PepsiCo, Inc. is the larger of the two by market cap, and PepsiCo, Inc. pays the higher dividend (4.08%). Which is the better fit depends on your goals.
| ABT | PEP | |
|---|---|---|
Market Cap | $166.94B | $198.15B |
Sector | Health | Consumer Staples |
52-Week High | $136.62 | $170.44 |
52-Week Low | $82.57 | $133.81 |
Enterprise Value | $193.69B | $240.05B |
Dividend Yield | 2.63% | 4.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
PepsiCo (PEP) trades at $144.6, up 0.91% on the day, with a bullish technical signal and recent earnings beats. The stock shows strong profitability with a 9.15% net margin and 43.92% ROE, though revenue growth remains modest at 2.2% year-over-year. Recent news highlights price cuts on snacks after consumer pushback on high prices, while the company prepares for Q1 2026 earnings next week.
The outlook is cautiously optimistic with a consensus price target of $161.73 (12% upside). Analyst sentiment leans neutral (63.64% Hold), balancing strong cash flow and brand power against pricing pressures and modest growth. Key risks include execution of North America turnaround and consumer sensitivity to price hikes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
